Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Inv. presentation
Director departure
Cyteir Therapeutics, Inc. (CYT) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/12/2023 8-K Quarterly results
10/05/2023 8-K Entry into a Material Definitive Agreement  Interactive Data
Docs: "99 Hayden LLC, a Delaware limited liability company , and Cyteir Therapeutics, Inc., a Delaware corporation . Background"
06/30/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Cyteir Therapeutics Announces Discontinuation of CYT-0851 Development Program and Planned Liquidation and Dissolution"
05/31/2023 8-K Resignation/termination of a director
04/03/2023 8-K Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits...
Docs: "Agreement”) is made as of March 29, 2023 , by and between 99 HAYDEN LLC, a Delaware limited liability company , and CYTEIR THERAPEUTICS, Inc., a Delaware corporation . RECITALS:"
03/23/2023 8-K Quarterly results
Docs: "Cyteir Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights - Initial data from Phase 1 combination with capecitabine in advanced ovarian cancer are expected in mid-2023 - Dose for the Phase 1 combination trials identified as 400mg daily - Ended 2022 with approximately $147 million in cash; Projected cash runway into 2026"
02/06/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
01/19/2023 8-K Cost Associated with Exit or Disposal Activities, Departure of Directors or Certain Officers; Election of Directors; Appointm...
Docs: "Cyteir Therapeutics Announces Prioritization of CYT-0851 Development and Extended Cash Runway - Encouraging early clinical results observed in treating ovarian cancer with CYT-0851 combination therapy - Strategic prioritization of clinical development of CYT-0851 combination therapy for ovarian cancer, together with deferral of other development activities, is expected to extend cash runway into 2026"
11/07/2022 8-K Quarterly results
08/08/2022 8-K Quarterly results
Docs: "INVESTOR CONTACT:"
06/17/2022 8-K Quarterly results
06/06/2022 8-K Quarterly results
05/05/2022 8-K Quarterly results
04/26/2022 8-K Regulation FD Disclosure  Interactive Data
Docs: "Agenda Introduction Markus Renschler, MD"
03/16/2022 8-K Quarterly results
02/25/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549"
02/24/2022 8-K Quarterly results
02/07/2022 8-K Quarterly results
01/11/2022 8-K Investor presentation
Docs: "Investor Presentation",
"Investor Presentation"
12/16/2021 8-K Quarterly results
11/12/2021 8-K Quarterly results
Docs: "CYTEIR THERAPEUTICS, INC CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Operating expenses: Research and development $ 8,205 $ 4,214 $ 22,704 $ 12,848 General and administrative 3,547 831 7,693 2,715 Total operating expenses 11,752 5,045 30,397 15,563 Loss from operations Other income : Other income 48 9 86 100 Total other income 48 9 86 100 Net loss $ $ $ $ Net loss per share—basic and diluted $ $ $ $ Weighted-average common stock outstanding—basic and diluted 35,062,900 1,463,084 14,229,834 1,428,311 CYTEIR THERAPEUTICS, INC CONDENSED BALANCE SHEETS September 30, 2021 Assets Current assets: Cash and cash equivalents $ 199,822 $ 10,938 Prepaid expenses and other current assets 4,397 1,193 Tot..."
08/09/2021 8-K Quarterly results
07/02/2021 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Second Amendment to Lease with 99 Hayden LLC"
06/25/2021 8-K Quarterly results

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy